EzySpot

Similar stories

Diabetes Drug Market Future Outlook 2 years 51 weeks ago

Global diabetes drug market is expected US$ 76 Billion by 2024. Renub Research report titled “Diabetes Drug Market, Oral (DPP IV Inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, Biguanide) Injection (Glucagon-like peptide (GLP) 1 agonist, Amylin Receptor Agonist), Insulin (Rapid – Acting Insulin, Long Acting Insulin, Premixed Insulin), Regions (United States, Europe, Japan, China, India, Brazil), Companies (Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson, Boehringer Ingelheim)” provides Diabetes Drug Market.

Lanreotide APIs 4 years 49 weeks ago

Lanreotide is a synthetic analogue of somatostatin, a naturally occurring inhibitory hormone which blocks the release of several other hormones, including growth hormone, thyroid-stimulating hormone (TSH), insulin and glucagon. Lanreotide binds to the same receptors as somatostatin, with higher affinity to peripheral receptors, and has similar activity.

Growth hormone releasing hormone 4 years 44 weeks ago

GHRH is a releasing hormone of growth hormone (GH). It is a 44-amino acid peptide hormone produced in the arcuate nucleus of the hypothalamus. GHRH is released from neurosecretory nerve terminals of these arcuate neurons, and is carried by the hypothalamo-hypophyseal portal system to the anterior pituitary gland, where it stimulates growth hormone (GH) secretion by stimulating the growth hormone-releasing hormone receptor. GHRH is released in a pulsatile manner, stimulating similar pulsatile release of GH.

Global Insulin Market Research Report 2018-2022 3 years 35 weeks ago

Insulin Market: Insulin is an anabolic hormone secreted by β-cells of pancreatic islets. Insulin helps in the metabolism of carbohydrates, proteins, and fats by absorbing the glucose and converts to glycogen by glycogenesis and stores in the skeletal muscles. Deficiency of insulin leads to the hyperglycemia or diabetes mellitus. Insulin is commonly used in type-1 diabetes, however, rarely used in the type 2 diabetes. The β-cells of the pancreas are destroyed due to the autoimmune reaction and causes insulin deficiency which leads to type-1 diabetes. In type 2 diabetes, the body becomes more resistant to insulin and requires more insulin for the carbohydrate metabolism.

Diabetes Drug Market Outlook 2 years 38 weeks ago

Diabetes is a health disorder in which the level of blood glucose gets elevated in the human body. Global Diabetes Drugs Market is projected to go beyond US$ 76 Billion by the end of the year 2024. Type 1 Diabetes: Type 1 diabetes also known by the name of juvenile or childhood-onset or insulin-dependent diabetes is characterized by the deficient insulin production and needs insulin administration daily. Type 2 Diabetes: Type 2 diabetes formerly known as adult-onset or non-insulin dependent diabetes results from the human body’s ineffective use of insulin.

Tasimelteon inhibitor 5 years 6 weeks ago

Tasimelteon (trade name Hetlioz) is a drug approved by the FDA solely for the treatment of non-24-hour sleep–wake disorder (often designated as N24HSWD) in totally blind adults. It is a selective agonist for the melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, similar to other members of the melatonin receptor agonist class of which ramelteon (2005) and agomelatine (2009) were the first approved.

Liraglutide Acetate 5 years 35 weeks ago

DOTA-(Tyr3)-Octreotate supplied by Creative Peptides is used in modern scientific research. Since biotech has become so important, such research could also be significant in the fields of life sciences. Feel interested in it please visit the site to know more details.